Who
Richard Klausner
Director
Company insider
Files Form 4 as: Executive Chairman, Lyell Immunopharma; Director, Parabilis Medicines; Director, Juno Therapeutics; Sr VP, Chief Medical Officer, Illumina.
In numbers
- Trades disclosed
- 74
- Buys
- 1
- Sells
- 22
- Bought
- $95K
- Sold
- $11.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 29 Jan 2014
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Bought | $95K158,000 at $0.60 | filing |
| 14 Jun 2024filed 17 Jun 2024 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 8 Sep 2023filed 8 Sep 2023 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 15 Aug 2023filed 17 Aug 2023 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $132K58,020 at $2.28 | filing |
| 16 Jun 2023filed 20 Jun 2023 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 23 Sep 2022filed 27 Sep 2022 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Sold | $71K11,100 at $6.40 | filing |
| 8 Jun 2022filed 10 Jun 2022 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 21 Jun 2021filed 23 Jun 2021 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code C | —3,765,842 | filing |
| 21 Jun 2021filed 23 Jun 2021 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,765,842 at $0.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $324K12,000 at $27.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $535K12,000 at $44.60 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $765K12,000 at $63.71 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code U | $61.4M705,525 at $87.00 | filing |
| 7 Feb 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code G | —23,250 at $0.00 | filing |
| 8 Jan 2018filed 9 Jan 2018 | Juno Therapeutics | SEC FORM 4 Sold | $91K1,949 at $46.85 | filing |
News
Illumina To Webcast Upcoming Investor ConferenceILMN · prnewswire.com · 20 Oct 2026Lyell Immunopharma (NASDAQ:LYEL) versus Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical ComparisonLYEL · themarketsdaily.com · 20 Oct 2026Reviewing Neuphoria Therapeutics (NASDAQ:NEUP) & Lyell Immunopharma (NASDAQ:LYEL)LYEL · dailypolitical.com · 18 Oct 2026Illumina's (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?ILMN · insidermonkey.com · 13 Oct 2026
0 headlines in the last 90 days name Richard Klausner; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.